{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/LXEO/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-29T16:09:34.177Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":10296,"canonical_name":"Lexeo Therapeutics, Inc.","cik":"0001907108","uei":null,"lei":null,"duns":null,"ticker":"LXEO"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":33},"count":33,"timeline":[{"ts":"2026-07-01","kind":"sec.form144","reporter":"Townsend Richard Nolan","title":"Officer, Director","shares":25947,"usd_value":116185,"security_title":"Common","approx_sale_date":"2026-07-01","accession_number":"0001959173-26-005031","importance":40.023237096},{"ts":"2026-07-01","kind":"sec.form144","reporter":"Bhalla Narinder Pal","title":"Officer","shares":22306,"usd_value":98684,"security_title":"Common","approx_sale_date":"2026-07-01","accession_number":"0001959173-26-005032","importance":40.019736794},{"ts":"2026-07-01","kind":"sec.form144","reporter":"Otero Jose Manuel","title":"Officer","shares":4666,"usd_value":20919,"security_title":"Common","approx_sale_date":"2026-07-01","accession_number":"0001959173-26-005036","importance":40.004183816},{"ts":"2026-07-01","kind":"sec.form144","reporter":"Tamayo Louis Edward","title":"Officer","shares":4641,"usd_value":20815,"security_title":"Common","approx_sale_date":"2026-07-01","accession_number":"0001959173-26-005033","importance":40.004162978},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Townsend Richard Nolan","title":"Chief Executive Officer","shares":25947,"price_per_share":4.48,"usd_value":116243,"security_title":"Common Stock","importance":35.11624256},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Bhalla Narinder Pal","title":"Chief Medical Officer","shares":22306,"price_per_share":4.42,"usd_value":98593,"security_title":"Common Stock","importance":35.09859252},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Otero Jose Manuel","title":"Chief Operating Officer","shares":4666,"price_per_share":4.48,"usd_value":20904,"security_title":"Common Stock","importance":35.02090368},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Tamayo Louis Edward","title":"Chief Financial Officer","shares":4641,"price_per_share":4.49,"usd_value":20838,"security_title":"Common Stock","importance":35.02083809},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — Lexeo Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001907108/144/0001959173-26-005031","accession_number":"0001959173-26-005031","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — Lexeo Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001907108/144/0001959173-26-005032","accession_number":"0001959173-26-005032","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — Lexeo Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001907108/144/0001959173-26-005033","accession_number":"0001959173-26-005033","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — Lexeo Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001907108/144/0001959173-26-005036","accession_number":"0001959173-26-005036","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — Lexeo Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001907108/4/0001995218-26-000013","accession_number":"0001995218-26-000013","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — Lexeo Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001907108/4/0002024096-26-000011","accession_number":"0002024096-26-000011","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — Lexeo Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001907108/4/0002083206-26-000005","accession_number":"0002083206-26-000005","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — Lexeo Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001907108/4/0002109299-26-000007","accession_number":"0002109299-26-000007","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"8-K","title":"8-K — Lexeo Therapeutics, Inc. — 2026-06-29","url_slug":"/sec/cik-0001907108/8-k/0001193125-26-288703","accession_number":"0001193125-26-288703","importance":35},{"ts":"2026-06-29","kind":"sec.filing","form_type":"4","title":"4 — Lexeo Therapeutics, Inc. — 2026-06-29","url_slug":"/sec/cik-0001907108/4/0001931514-26-000002","accession_number":"0001931514-26-000002","importance":30},{"ts":"2026-06-29","kind":"sec.insider.a","reporter":"Townsend Richard Nolan","title":"Chief Executive Officer","shares":67000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-29","kind":"sec.insider.a","reporter":"Otero Jose Manuel","title":"Chief Operating Officer","shares":12060,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-29","kind":"sec.insider.a","reporter":"Tamayo Louis Edward","title":"Chief Financial Officer","shares":12000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-29","kind":"sec.insider.a","reporter":"Bhalla Narinder Pal","title":"Chief Medical Officer","shares":55000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-15","kind":"sec.filing","form_type":"8-K","title":"8-K — Lexeo Therapeutics, Inc. — 2026-06-15","url_slug":"/sec/cik-0001907108/8-k/0001193125-26-270275","accession_number":"0001193125-26-270275","importance":35},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Lexeo Therapeutics, Inc. — 2026-05-20","url_slug":"/sec/cik-0001907108/4/0001995218-26-000011","accession_number":"0001995218-26-000011","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Lexeo Therapeutics, Inc. — 2026-05-20","url_slug":"/sec/cik-0001907108/4/0002024096-26-000009","accession_number":"0002024096-26-000009","importance":30},{"ts":"2026-05-18","kind":"sec.form144","reporter":"Townsend Richard Nolan","title":"Officer, Director","shares":3342,"usd_value":16927,"security_title":"Common","approx_sale_date":"2026-05-18","accession_number":"0001959173-26-003723","importance":40.00338538},{"ts":"2026-05-18","kind":"sec.form144","reporter":"Adler Eric","title":"Officer","shares":1595,"usd_value":8074,"security_title":"Common","approx_sale_date":"2026-05-18","accession_number":"0001959173-26-003716","importance":40.001614746},{"ts":"2026-05-18","kind":"sec.form144","reporter":"Otero Jose Manuel","title":"Officer","shares":1302,"usd_value":6606,"security_title":"Common","approx_sale_date":"2026-05-18","accession_number":"0001959173-26-003717","importance":40.00132127},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Townsend Richard Nolan","title":"Chief Executive Officer","shares":3342,"price_per_share":5.0649,"usd_value":16927,"security_title":"Common Stock","importance":35.0169268958},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Otero Jose Manuel","title":"Chief Operating Officer","shares":1302,"price_per_share":5.074,"usd_value":6606,"security_title":"Common Stock","importance":35.006606348},{"ts":"2026-05-18","kind":"sec.filing","form_type":"144","title":"144 — Lexeo Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001907108/144/0001959173-26-003716","accession_number":"0001959173-26-003716","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"144","title":"144 — Lexeo Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001907108/144/0001959173-26-003717","accession_number":"0001959173-26-003717","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"144","title":"144 — Lexeo Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001907108/144/0001959173-26-003723","accession_number":"0001959173-26-003723","importance":30}]}